EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of a Polycaprolactone-Based Injectable Filler for the Correction of Mild-to-Moderate Chin Retrusion in Adults Compared with No Treatment: A Multicenter, Randomized Controlled Study

Chang Shu, Chenyu Zhu, Feng Li, Wei Du, Wei Wang, Xin Sun, Linfeng Li, Xiumin Yang, Yaling Liu, Qiuning Sun

Aesthetic Plastic Surgery · 15.11.2026

DOI: 10.1007/s00266-026-06332-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aesthetic Plastic Surgery, online erschienen am 15.11.2026. Verfasst von Chang Shu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifu…. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Shandong Caicai Medical Technology Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chin retrusion is a common aesthetic concern that disrupts lower facial balance. Polycaprolactone (PCL)-based injectable filler provides immediate volumization and stimulates endogenous collagen production, offering a nonsurgical approach to chin contour enhancement. METHODS: This multicenter, randomized, evaluator-blinded, no-treatment-controlled trial enrolled 162 adults with mild-to-moderate chin retrusion [Genial Chin Retrusion Scale (GCRS) grades 1-2]. Subjects were randomized 2:1 to PCL-based injectable filler treatment or no treatment. The primary endpoint was the proportion of GCRS responders, defined as improvement of at least one grade from baseline by blinded-evaluator assessment at Week 24. Secondary endpoints included GCRS response, Global Aesthetic Improvement Scale scores assessed by investigators and subjects, and subject-reported satisfaction through Week 60 in treated subjects and Week 24 in controls. Safety assessments included adverse events, injection-site reactions, and laboratory testing. RESULTS: At Week 24, GCRS response rates were higher in the PCL group than in the no-treatment control group (93.33% vs. 0%; difference, 93.33%; 95% confidence interval 84.07-96.73%; P < 0.001). Improvements in GCRS, investigator- and subject-rated Global Aesthetic Improvement Scale scores, and satisfaction were observed under trial conditions, with improvement in treated subjects maintained descriptively through Week 60. Injection-site reactions occurred in 85.71% of treated subjects and were predominantly mild and transient. Device-related treatment-emergent adverse events were infrequent. No serious device-related adverse events occurred. CONCLUSIONS: PCL-based injectable filler was effective and well tolerated for correcting mild-to-moderate chin retrusion compared with no treatment. These findings do not establish comparative effectiveness versus active treatments or clinical superiority. STUDY DESIGN: Prospective, multicenter, randomized controlled trial comparing the study product with no treatment. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Schlagwörter

Stichwörter der Autor:innen

Biostimulatory fillerChin augmentationChin retrusionNonsurgical aesthetic treatmentPolycaprolactone injectable fillerRandomized controlled trial

Autor:innen und Institutionen

  • Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, People's Republ…
  • Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.
  • Department of Dermatology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, People's Republic of China.
  • Department of Dermatology, The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, Hebei, People's Republic of China.

Förderung

  • Shandong Caicai Medical Technology Co., Ltd.

Zitieren

APA

Shu, C., Zhu, C., Li, F., Du, W., Wang, W., Sun, X., Li, L., Yang, X., Liu, Y., & Sun, Q. (2026). Efficacy and Safety of a Polycaprolactone-Based Injectable Filler for the Correction of Mild-to-Moderate Chin Retrusion in Adults Compared with No Treatment: A Multicenter, Randomized Controlled Study. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-026-06332-x

Vancouver

Shu C, Zhu C, Li F, Du W, Wang W, Sun X, et al. Efficacy and Safety of a Polycaprolactone-Based Injectable Filler for the Correction of Mild-to-Moderate Chin Retrusion in Adults Compared with No Treatment: A Multicenter, Randomized Controlled Study. Aesthetic Plastic Surgery. 2026. doi:10.1007/s00266-026-06332-x

BibTeX
@article{Shu2026,
  author = {Shu, Chang and Zhu, Chenyu and Li, Feng and Du, Wei and Wang, Wei and Sun, Xin and Li, Linfeng and Yang, Xiumin and Liu, Yaling and Sun, Qiuning},
  title = {Efficacy and Safety of a Polycaprolactone-Based Injectable Filler for the Correction of Mild-to-Moderate Chin Retrusion in Adults Compared with No Treatment: A Multicenter, Randomized Controlled Study},
  journal = {Aesthetic Plastic Surgery},
  year = {2026},
  doi = {10.1007/s00266-026-06332-x}
}
Kostenlos starten →